Why Liver Cancer Screening Needs Better Blood-Based Options?

Liver cancer can develop quietly. Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, may cause few noticeable symptoms during its early stages. For people at increased risk, this makes regular surveillance particularly important.

Blood testing can provide useful information, but not all liver cancer blood tests look for the same thing. Traditional testing often measures alpha-fetoprotein (AFP), a protein that may be elevated in people with HCC. However, many patients with HCC have normal AFP levels. MoleculeDx takes a different approach by looking for cancer-associated fusion transcript signals circulating in the blood.

Why Is Early Liver Cancer Detection Challenging?

HCC does not produce one universal blood marker that is present in every patient. Tumors are biologically diverse, and molecular signals can vary from one cancer to another.

That is one reason relying on a single biomarker can be limiting. A blood-based molecular approach can instead examine several cancer-associated signals simultaneously, providing another source of information for liver cancer screening.

What Are Fusion Transcripts?

Cancer cells can acquire changes in their chromosomes that join parts of two different genes. These rearrangements can create fusion genes, which may produce corresponding RNA molecules called fusion transcripts.

Research underlying the MoleculeDx technology has identified selected fusion transcripts in the serum of patients with HCC as circulating cell-free RNA.

In simpler terms, instead of measuring a conventional protein such as AFP, the approach looks for molecular signals associated with genetic changes in cancer cells.

Why Look for Multiple Signals?

No single fusion transcript is expected to occur in every liver cancer.

The Liver Cancer Fusion Predictor therefore uses a multi-marker approach. Multiple cancer-associated fusion transcript signals are evaluated together rather than depending on a single marker. The underlying Fusion-detect™ technology is designed to detect these fusion transcript signals in blood or serum.

This distinction is important:

Liver Cancer Fusion Predictor is the name of the HCC blood test, while Fusion-detect™ refers to the underlying fusion-transcript detection technology.

What Does a Blood Test Result Mean?

A liver cancer blood test is a screening tool, not a substitute for a complete medical evaluation.

A positive molecular result can identify signals associated with HCC and indicate the need for appropriate clinical follow-up. A negative result does not completely exclude cancer. Imaging, clinical assessment, individual risk factors and other information remain important in determining what should happen next.

Patients should discuss their results and appropriate follow-up with a qualified healthcare professional.

Who Should Think About Liver Cancer Screening?

People at increased risk of HCC should discuss an appropriate surveillance strategy with their healthcare providers. Risk can be associated with chronic liver disease, including cirrhosis and chronic viral hepatitis.

The important question is not simply whether a blood test is available, but which screening approach is appropriate for an individual’s risk and how the result will be used in ongoing care.

A New Molecular Window Into Liver Cancer:

More than a decade of peer-reviewed research underlying the MoleculeDx platform has investigated cancer-associated fusion genes and fusion transcripts, including their presence in HCC tissue and serum.

The goal of blood-based molecular screening is straightforward: obtain useful information about cancer-associated signals from an easily accessible blood sample.

For people concerned about their liver cancer risk, the Liver Cancer Fusion Predictor offers a molecular approach based on detecting multiple cancer-associated fusion transcript signals in the blood.